### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2021

ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

001-31812

(Commission File Number)

58-2301143 (IRS Employer Identification No.)

56623

(Zip Code)

210 Main Street West Baudette, Minnesota

(Address of principal executive offices)

Registrant's telephone number, including area code: (218) 634-3500

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Common Stock

Delaware

(State or other jurisdiction of

incorporation)

Trading Symbol(s): ANIP Name of each exchange on which registered: Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

### Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 2, 2021, ANI Pharmaceuticals, Inc. (the "Company") held its 2021 annual meeting of stockholders (the "Annual Meeting"). The following sets forth the matters that were voted upon by the Company's stockholders at the Annual Meeting and the voting results for such matters. These matters are described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2021 (the "Proxy Statement").

1. The Company's stockholders voted to elect the following directors, each to serve until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The final voting results are as follows:

Nominee	For	Against	Abstentions	Broker Non-Votes
1. Robert E. Brown, Jr.	9,466,522	325,176	3,376	797,905
2. Thomas Haughey	9,534,467	257,199	3,408	797,905
3. Nikhil Lalwani	9,655,278	136,331	3,465	797,905
4. David B. Nash, M.D., M.B.A.	9,409,937	381,762	3,375	797,905
5. Antonia R. Pera	9,656,007	135,634	3,433	797,905
6. Jeanne A. Thoma	9,652,137	139,542	3,395	797,905
7. Patrick D. Walsh	9,392,837	398,827	3,410	797,905

2. The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Proxy Statement. The final voting results are as follows:

	For	Against	Abstentions	Broker Non-Votes
	9,417,485	328,111	49,478	797,905
3.	The Company's stockholders ratified the appointment	t of EisnerAmper LLP as the Company's independent r	egistered public accounting firm for the year ending D	ecember 31, 2021. The final voting results are as follows:
	For	Against	Abstentions	Broker Non-Votes
	10,546,523	42,147	4,309	

The Company's stockholders approved in connection with the Company's pending acquisition of Novitium Pharma LLC ("Novitium"), the issuances of (a) 2,466,667 shares of common stock to certain members of Novitium and (b) 25,000 shares of Series A Convertible Preferred Stock to Ampersand 2020 Limited Partnership. The final voting results are as follows: 4.

For	Against	Abstentions	Broker Non-Votes
9,727,248	57,285	10,541	797,905

### Item 7.01. Regulation FD Disclosure.

On June 4, 2021, the Company posted an investor presentation to the Investor Relations section of its website at www.anipharmaceuticals.com in connection with a presentation by its executives at an investor conference. A copy of the investor presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, are furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit</u>	Description
<u>99.1</u>	<u>Investor Presentation – June 2021.</u>
104	Cover Page Interactive Data File (embedded within the inline XBRL document).

### SIGNATURES

By:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANI PHARMACEUTICALS, INC.

/s/ Stephen P. Carey Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer

Dated: June 4, 2021



# Jefferies Healthcare Conference

June 2021



## Disclaimer

### Cautionary Note Regarding Forward-Looking Statements

This presentation contemplates the acquisition by ANI Pharmaceuticals, Inc ("ANI" or the "Company") of Novitium Pharma, LLC ("Novitium") and contains forward-looking statements, including information about management's view of ANI's and Novitium's future expectations, plans and prospectus, as well as other forward-looking statements, including the potential benefits from the acquisition of new drug applications and an abbreviated new drug application for Sandoz, Inc. and the timing for submission of the sNDA for Cortrophin Gel. Any statements indove known and unknown in siks, uncertainties and other factors, which may cause actual results to be material dytifierent than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown in gring distance expressed or implied in such statements. Unknown or unpredictable factors subcidable factors about an aterial adverse effects on the Company's future results. Information concerning these and thirfs with the Socurities and Exchange Commission (SEC). The forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic reports and filings with the Socurities and Exchange Commission (SEC). The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements and you should not place undue reliance on these forward-looking statements.

### No Offer or Solicitation

This presentation is for informational purposes only and is neither an offer to sell or purchase, nor a solicitation of an offer to sell, buy or subscribe for any securities, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"), or an exemption therefrom.

### Use of Projections

This presentation contains financial forecasts with respect to, among other things, income sources, revenue growth, and equity values. These unaudited financial projections should not be relied upon as being necessarily indicative of future results. The inclusion of the unaudited financial projections in this presentation is not an admission or representation that such information is material. The assumptions and estimates underlying the unaudited financial projections are information are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the unaudited financial projections. There can be no assume that the prospective results are indicative of future performance or that actual results will not differ materially from those presented in the unaudited financial projections. Inclusion of the unaudited financial projections in this presentation hose are expresentation by any person that the results contained in the unaudited financial projections will be achieved.

### Industry and Market Data

The information contained here also includes information provided by third parties. None of ANI, Novitium, their respective affiliates and any third parties that provided information to ANI or Novitium provide guarantees of the accuracy, completeness and timeliness or availability of the information. None of ANI, Novitium and any of their respective affiliates nor any of the research providers are responsible for any errors or omissions or conclusions form the use of such content.


### Non-GAAP Financial Measures

Non-GAAP Financial Measures
This presentation includes certain non-GAAP financial measures, including Adjusted EBITDA and Adjusted Gross Margin, that management reviews to evaluate its business, measure its performance and make strategic decisions. Management believes that such non-GAAP financial measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as management. Adjusted EBITDA is a non-GAAP financial measure that represents net income prior to interest expense, net, other expense, net, income taxes, and depreciation and amortization, as adjusted to add back certain non-cesh and non-recurring charge. Adjusted EBITDA and any other ratio or metrics dived therefrom are financial measures to calculated in accordance with GAAP and should not be considered as substitutes for revense, net, income taxes, and depreciation and amortization, as adjusted to add back certain non-cesh and non-recurring charge. Adjusted EBITDA and any other ratio or metrics dived therefrom are financial measures to analyze the business would have material limitations because their calculations are based on the subjective determination of management regarding the nature and classification of events and circumstances that investors may find significant. In addition, atthough other comparities in its industry may report measures titled Adjusted EBITDA or similar measures, such non-GAAP financial measures may be calculated differently from how management calculates its non-GAAP financial measures, which reduces their overall usefulness as comparitive measures. Because of these limitations, you should consider Adjusted EBITDA and EBITDA and any other reportance measures, including net income and other financial results presented in accordance with GAAP. Please refer to Appendix A in this presentation for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measure.




# Company Snapshot

Poised for sustainable growth






### Strong and Growing U.S.-Focused and Diversified BioPharma Company





© 2021 ANI Pharmaceuticals, Inc.

## **Proven Strong Growth Profile**



# **Strong Business Development Engine to Fuel Growth**


Brands – 9 Deals			
Class	Seller	Products	
2018 AZ	47	Atacand & Atacand HCT	
	AZ	Casodex & Arimidex	
2017	2017 Cranford	Inderal XL	
2017		Innopran XL	
2016	Akrimax	Inderal LA/Prop ER	
2016	Merck	Cortrophin	
2014	Shire	Vancocin assests	
	Noven	Lithobid	
2011	Meda	Reglan	

Class	Seller	Products
	Harris	Fluconazole
2020	Ricon	Clobetasol cream
	Amerigen	23 Gx Products
	Coeptis	7 Gx Products
2019	Cambrex	Lidocaine
	Pii	Bretylium
	Teva	31 ANDAs
	Аррсо	Ranitidine + Chlorzoxazone
2018	Impax	7 Gx Products
	IDT	23 ANDAs
2016	Aspen	Brethine
2016	H2	Lipofen AG + HC Rectal Cream
2015	Teva	Basket #2 – 22 ANDAs
2015	Teva	Flecainide
2013	Teva	Basket #1 – 31 ANDAs
2013	Sofgen	Nimodipine + Omega



© 2021 ANI Pharmaceuticals, Inc.

### Four Pillars to Drive Sustainable Growth



Empowered best-in-class experienced talent retaining core strengths and driving growth



### Analysts' estimate of Acthar Gel US Annual Sales by Indication<sup>(1)</sup>


## **CORTROPHIN GEL:** Transformational opportunity

**sNDA filing on track** for June 2021 submission to FDA

٢

B

Only repository corticotropin (Acthar Gel) available on the market estimated to have sales of approximately **\$640** - **\$700 million** in next three years






© 2021 ANI Pharmaceuticals, Inc.


Actual

Expected

### Novitium acquisition: adds best-in-class R&D engine with Generics and 505(b)(2) capabilities 14 9 ~13 Average filing to approval time 2017 2018 ~10 Average approval to launch time Products launched within 95% seven days of approval 4 Management have developed and commercialized over 100 specialty dosage forms 2018 and ANDAs in the US

Annual ANDA Filling<sup>(1)</sup>






(1) Inclusive of partnered prod




© 2021 ANI Pharmaceuticals, Inc.

### **Expanding Established Brands Portfolio Products: Derm Acquisition**



### **Significant North American Manufacturing Footprint**

with ample capacity and excellent GMP track record



### **Executive Leadership Team with Broad Industry Expertise**



#### Nikhil Lalwani President & Chief Executive Officer

- 20+ years leadership experience in pharmaceuticals and
- healthcare Proven track record of developing and executing multi-year



#### James Marken SVP, Operations & Product Development

Samy Shanmugam\*

Ori Gutwerg SVP, Generics

products

Novitium President & Co-Founder

30+ years of pharmaceuticals experience, overseeing production and logistical functions for company facilities Expertise in quality control, validation and manufacturing

Former Head of R&D and Operations for Par Pharmaceuticals

Founded Edict Pharmaceuticals, Nuray chemicals and Ethics BioLab Developed over 100 speciality dosage forms and ANDAs in the US

17+ years pharmaceutical experience across generic and branded

Proven track record of business development and accelerating growth



PAR

NAVEL

TARD

Cipla

McKinsey & Company



Stephen Carey SVP, Finance & Chief Financial Officer 25+ years financial executive experience Former SVP. Controller and Principal Accounting Officer for Par Pharmaceuticals



### Chris Mutz




Head of Rare Diseases/Cortrophin 20+ years commercialization experience Responsible for building and leading launch of Soliris for gMG and NMOSD in the US



### Chad Gassert\*

Novitium Chief Executive Officer, Co-Founder Former SVP of Business Development, M&A, Partnerships and Licensing for PAR Par Pharmaceuticals Formulation development scientist for Sandoz SANDOZ





© 2021 ANI Pharmaceuticals, Inc.



# Thank You!



## Appendix

(unaudited, in thousand	(s)
	Year Ended December 31, 2020
Net (Loss)/Income	\$ (22,548
Add/(Subtract):	
Interest expense, net	9,452
Other expense, net	494
Provision/(Benefit) for income taxes	(3,414
Depreciation and amortization	44,638
Cortrophin pre-launch charges	11,263
Expensed FDA approval milestone payment	
Stock-based compensation(1)	9,470
CEO transition items <sup>(2)</sup>	7,386
Cortrophin team restructuring	401
Acquired IPR&D expense	3,784
Excess of fair value over cost of acquired inventory	4,296
Asset impairments(3)	1,330
Charges related to market exits	567
Transaction and integration expenses	
Adjusted non-GAAP EBITDA	\$ 67,119
Proforma Adjustment for April 2021 acquisition:	
EBITDA contribution from acquired products	8,500
Proforma 2020 Adjusted EBITDA	\$ 75.619

<sup>(1)</sup> For the year ended December 31, 2020. Stock-based compensation excludes \$3.4 million of stock-based compensation expense associated with the departure of our former President and CEO. This amount is included in this table as part of CEO transition items.

<sup>(2)</sup> CEO transition items for the year ended December 31, 2020 is comprised of \$3.4 million of stock-based compensation expense and \$3.1 million of expense for salary continuation, bonus and other fringe benefits associated with the departure of our former President and CEO, as well as certain legal and recruiting costs related to the search for a permanent replacement.

(ii) For the year ended December 31, 2020, Asset impairments is comprised of finished goods inventory reserves for Bretylium, accounts receivable reserves due to customer bankruptoy, and the impairment of the marketing and distribution right intangible asset, tempered by a modest recovery of previously reserved inventory related to market exits. For the three and twelve month period ended December 2019, Asset impairments was comprised of the impairment of a product right intangible asset.

